Daunorubicin-60 versus daunorubicin-90 versus idarubicin-12 for induction chemotherapy in acute myeloid leukemia: a retrospective analysis of the Mayo Clinic experience

Haematologica. 2022 Oct 1;107(10):2474-2479. doi: 10.3324/haematol.2022.281045.

Authors

Ayalew Tefferi¹, Naseema Gangat¹, Mithun Shah¹, Hassan Alkhateeb¹, Mrinal S Patnaik¹, Aref Al-Kali¹, Michelle A Elliott¹, William J Hogan¹, Mark R Litzow¹, Christopher C Hook¹, Abhishek Mangaonkar¹, David Viswanatha², Dong Chen², Animesh Pardanani¹, Rhett P Ketterling³, Kebede H Begna⁴

Affiliations

¹ Department of Internal Medicine and Division of Hematology.
² Division of Hematopathology.
³ Division of Cytogenetics, Department of Laboratory Medicine, Mayo Clinic, Rochester, MN.
⁴ Department of Internal Medicine and Division of Hematology. begna.kebede@mayo.edu.

No abstract available

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / adverse effects
Cytarabine / therapeutic use
Daunorubicin / therapeutic use
Humans
Idarubicin* / therapeutic use
Induction Chemotherapy
Leukemia, Myeloid, Acute* / drug therapy
Remission Induction
Retrospective Studies

Substances

Cytarabine
Idarubicin
Daunorubicin